All humor aside, I do understand what you are saying, dcspka.
I personally like more concrete evidence in a biotech, but everyone's risk tolerance is different. I like rumors, but I like rumors created by a good solid Phase II clinical or FDA clearance of a 510(k).
Of course, many drugs fail in Phase III and many devices fail in the real world after getting FDA clearance. But who knows, maybe Radient will find a way to get more funding, hire Chang, and develop a cancer vaccine.
Unfortunately, I think that will require a reorganization that cancels all current shares and restructures the debt. But, that is just my opinion.
Best of luck to all shareholders!
